Symbols

RXRX

Recursion·NASDAQ

--(--)

RXRX fundamentals

RXRX Q4 2025 Earnings

Recursion (RXRX) released its earnings on Feb 25, 2026: revenue was 35.35M (YoY +683.66%), beat estimates; EPS was -0.21 (YoY +60.38%), beat estimates.

Revenue / YoY

35.35M

+683.66%

EPS / YoY

-0.21

+60.38%

Report date

Feb 25, 2026

RXRX Earnings Call Summary for Q4,2025

Clinical Milestones: First-in-class FAP data (43% polyp reduction) and 5th Sanofi milestone validate AI-driven drug discovery.
Platform Efficiency: 90% fewer compounds synthesized, 17-month vs. 42-month industry average for IND-enabling studies.
Financial Discipline: 35% YoY expense reduction, $754M cash, runway to 2028.
Strategic Partnerships: $500M+ partner inflows, 5 lead programs with Sanofi.
Speed to Clinic: 242 compounds designed for PI3K in 10 months; enrollment rates 1.3-1.6x industry standard.

Earnings

EPS

Revenue

Revenue & Expenses

RXRX has released its 2025 Q4 earnings report, with revenue of 35.54M, reflecting a YoY change of 681.74%, and net profit of -108.12M, showing a YoY change of 39.56%. The Sankey diagram below clearly presents RXRX's revenue sources and cost distribution.

Key Indicators

Recursion (RXRX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Recursion (RXRX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Recursion (RXRX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Recursion (RXRX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown